Regeneron And Sanofi's Dupixent Approved In Japan As First Targeted Medicine For Adults With Moderate-To-Severe Bullous Pemphigoid

Regeneron and Sanofi's Dupixent has been approved in Japan as the first targeted treatment for adults with moderate-to-severe bullous pemphigoid (BP). The approval was based on pivotal trial results indicating that Dupixent patients experienced over four times more sustained disease remission through Week 36 compared to those on placebo. This marks the seventh approved indication for Dupixent in Japan.